FDA Approved Drugs » 2012
Medical Areas: Endocrinology | Urology

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

Bio-T-Gel (testosterone gel)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Teva Pharmaceutical
Approval Status: Approved February 2012
Treatment Area: hypogonadism

General Information

Bio-T-Gel is a clear, colorless hydroalcoholic gel containing testosterone. Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. Male hypogonadism results from insufficient secretion of testosterone and is characterized by low serum testosterone concentrations. Testosterone gel delivers amounts of testosterone that approximate normal concentrations seen in healthy men.

Bio-T-Gel was specifically approved for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

Bio-T-Gel is supplied as a gel for topical administration. The recommended dose is 50 mg of testosterone applied topically once daily in the morning to dry, intact skin on the shoulders and upper arms. The dose can be adjusted between a minimum of 50 mg of testosterone and a maximum of 100 mg of testosterone.

Clinical Results

FDA Approval
The FDA approval of Bio-T-Gel was based on a multi-center, randomized, parallel-group, active-controlled, 180 day trial in 227 hypogonadal men. The study was conducted in 2 phases. During the Initial Treatment Period (Days 1 to 90), 73 subjects were randomized to testosterone gel 5 g daily, 78 subjects to testosterone gel 10 g daily, and 76 subjects to a non-scrotal testosterone transdermal system. The study was double-blind for dose of testosterone gel but open-label for active control. Subjects who were originally randomized to testosterone gel and who had single-sample serum testosterone levels above or below the normal range on Day 60 were titrated to 7.5 g daily on Day 91. During the Extended Treatment Period (Days 91 to 180), 51 subjects continued on testosterone gel 5 g daily, 52 subjects continued on testosterone gel 10 g daily, 41 subjects continued on a non-scrotal testosterone transdermal system (5 mg daily), and 40 subjects received testosterone gel 7.5 g daily. Mean peak, trough and average serum testosterone concentrations within the normal range (298 to 1043 ng/dL) were achieved on the first day of treatment with doses of 5 g and 10 g. In subjects continuing on testosterone gel 5 g and 10 g, these mean testosterone levels were maintained within the normal range for the 180-day duration of the original study. Testosterone concentrations were maintained as long as the subject continued to properly apply the prescribed testosterone gel treatment.

Side Effects

Adverse events associated with the use of Bio-T-Gel may include, but are not limited to, the following:

  • acne
  • application site reaction
  • abnormal lab tests
  • prostatic disorders

Mechanism of Action

Bio-T-Gel is a clear, colorless hydroalcoholic gel containing testosterone. Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. Male hypogonadism results from insufficient secretion of testosterone and is characterized by low serum testosterone concentrations. Testosterone gel delivers physiologic amounts of testosterone, producing circulating testosterone concentrations that approximate normal concentrations seen in healthy men. Testosterone gel provides continuous transdermal delivery of testosterone for 24 hours following a single application to intact, clean, dry skin of the shoulders, upper arms and/or abdomen.

Additional Information

For additional information regarding Bio-T-Gel or hypogonadism, please visit the Teva web page.

 

 

 

 

Bipolar World   1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010
Owners:  Allie Bloom, David Schafer, M.Ed. (Blackdog)

Partners:  John Haeckel, Judith (Duff)
Founder:  Colleen Sullivan
Email Us at Bipolar World


About Us  Add a Link  Advance Directives  Alternative Treatments  Ask the Doctor   Ask Dr. Plyler about Bipolar Disorder   Ask The Doctor/Topic Archives  Awards  Benny the Bipolar Puppy  Bipolar Chat  Bipolar Children  Bipolar Disorder News  Bipolar Help Contract  Bipolar World Forums  Book Reviews  Bookstore  BP & Other mental Illness   Clinical Research Trials & FDA Drug Approval   Community Support   Contact Us  The Continuum of Mania and Depression   Coping   Criteria    Criteria and Diagnosis  Criteria-World Health Disabilities,  DSMV-IV   Dual Diagnosis  eGroups  Expressions (Poetry, Inspiration, Humor, Art Gallery, Memorials  Family Members   Getting Help for a Loved One who Refuses Treatment  Greeting Cards  History of Mental Illness  Indigo  Job and School  Links    Medications   Medication and Weight Gain    News of the Day  Parent Chat  Pay for Meds  Personal Stories  Self Help  Self Injury  Significant Others  Stigma and Mental Health Law  Storm's Column  Suicide!!!  The Suicide Wall  Table of Contents  Treatments  Treatment Compliance  US Disability  Veteran's Chat  What's New?